Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Increased plasma levels of galectin-1 in pancreatic cancer, potential use as biomarker

  • Martínez Bosch, Neus|||0000-0003-3596-0039
  • Barranco, Luis E.
  • Orozco, Carlos A.
  • Moreno Martínez-Losa, Mireia|||0000-0002-4365-4341
  • Visa, Laura|||0000-0002-3409-8857
  • Iglesias, Mar|||0000-0002-2274-4671
  • Oldfield, Lucy
  • Neoptolemos, John P.|||0000-0002-6201-7399
  • Greenhalf, William
  • Earl, Julie
  • Carrato, Alfredo|||0000-0001-7749-8140
  • Costello, Eithne
  • Navarro, Pilar|||0000-0003-4314-4584
Pancreatic ductal adenocarcinoma (PDA) is the most frequent type of pancreatic cancer and one of the deadliest diseases overall. New biomarkers are urgently needed to allow early diagnosis, one of the only factors that currently improves prognosis. Here we analyzed whether the detection of circulating galectin-1 (Gal-1), a soluble carbohydrate-binding protein overexpressed in PDA tissue samples, can be used as a biomarker for PDA. Gal-1 levels were determined by ELISA in plasma from healthy controls and patients diagnosed with PDA, using three independent cohorts. Patients with chronic pancreatitis (CP) were also included in the study to analyze the potential of Gal-1 to discriminate between cancer and inflammatory process. Plasma Gal-1 levels were significantly increased in patients with PDA as compared to controls in all three cohorts. Gal-1 sensitivity and specificity values were similar to that of the CA19-9 biomarker (the only FDA-approved blood test biomarker for PDA), and the combination of Gal-1 and CA19-9 significantly improved their individual discriminatory powers. Moreover, high levels of Gal-1 were associated with lower survival in patients with non-resected tumors. Collectively, our data indicate a strong potential of using circulating Gal-1 levels as a biomarker for detection and prognostics of patients with PDA.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Predictors of Metachronous Risk Polyps After Index Colonoscopy

  • Carot, Laura|||0000-0001-6507-9571
  • Navarro Viu, Gemma|||0000-0001-7906-5437
  • Naranjo-Hans, Dolores|||0000-0002-4089-047X
  • Iglesias, Mar|||0000-0002-2274-4671
  • Dalmases, Alba
  • Fernández Ibarrondo, Lierni|||0000-0003-2612-0484
  • Seoane, Agustín|||0000-0001-8023-4445
  • Buron, Andrea|||0000-0003-3590-1303
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Bessa Caserras, Xavier|||0000-0003-4680-1228
  • Andreu, Montserrat|||0000-0003-4286-1098
  • Alvarez-Urturi, Cristina|||0000-0002-7305-9973
We included patients with high-risk lesions (HRLs), defined as advanced adenoma (AA), large serrated polyps (SPs), and multiplicity (≥3 of any adenomas/SPs). Data on age, sex, cardiovascular risk factors, pharmacological treatment, and the histological characteristics in each individual, and mutations in genes involved in the most advanced index polyp, were collected. Parameters independently associated with a metachronous HRL diagnosis were evaluated through univariate and multivariate analyses. The results are reported as odds ratios and 95% confidence intervals along with P values. A total of 537 cases (median age: 60.7 years; 66% male) were included. Dyslipidemia and smoking correlated with metachronous HRLs. Multivariate logistic regression analysis showed that the presence of multiplicity with ≥3 polyps on the index colonoscopy was significantly associated with metachronous HRL, AA, proximal AA, and ≥3 polyps at 3 years. In addition, independent predictors of metachronous proximal AA were increasing age, female sex, and the loss of expression of the MLH1 protein. Multiplicity was a strong predictor of HRLs at 3 years, although the inclusion of other clinical variables (age, sex, smoking status, and dyslipidemia) improves surveillance recommendations. Without these risk factors, the surveillance could be extended to 5 years; we propose examining the somatic expression of MHL1 in all patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diagnostic value of genotypic analysis in primary cutaneous lymphomas using standardized biomed-2 polymerase chain reaction protocols, Experience in daily clinical practice

  • López Aventín, Daniel|||0000-0001-5097-5621
  • Gallardo, Fernando|||0000-0002-8996-3828
  • Colomo, Luis|||0000-0001-5236-5085
  • Moragón, Ester
  • Vela, María Carmen
  • Duran-Jordà, Xavier|||0000-0001-8517-9254
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Pujol Vallverdú, Ramón M|||0000-0002-5622-6055
BIOMED-2 Concerted Action BMH4-CT98-3936 (BIO-MED-2) PCR protocols are an important diagnostic tool in the evaluation of cutaneous lymphomas. The aim of this study was to assess the diagnostic value of the genotyping results obtained by these techniques in daily clinical practice. A total of 360 paraffin-em-bedded skin samples were retrospectively reviewed from 114 cutaneous T-cell lymphomas and 35 cutaneous B-cell lymphomas. A total of 249 biopsies from 180 patients with benign lymphoid infiltrates served as controls. T-cell receptor and immunoglobulin gene rearrangements were assessed using the BIOMED-2 method. A combined T-cell receptor gamma and beta assay approach reliably distinguished cutaneous T-cell lymphomas from benign skin T-cell infiltrates (sen-sitivity 89.4%; specificity 81.5%). Analysis of com-plete immunoglobulin heavy chain rearrangements also differentiated cutaneous B-cell lymphomas from benign B-cell infiltrates (sensitivity 85.7%; specificity 82.4%). In conclusion, the full BIOMED-2 protocol is a useful aid combined with clinical, histological and immunophenotypical findings for assessment of lym-phoid clonality in skin lymphoid proliferations.